![](images/graphics/blank.gif)
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
9
lượt xem 1
download
lượt xem 1
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial for patients with EGFR mutations.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD